In the specialized field of biochemical research, the par 4 peptide—specifically the PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2)—has become a cornerstone for investigators studying cellular signaling pathways. As someone who has followed the progression of peptide synthesis and its application in in vitro experimental mode PAR-4 (prostate apoptosis response-4) was identified as a protein that is upregulated in prostate tumor cells undergoing apoptosis. ls, I find the specificity of this tool particularly fascinating.
Understanding the Mechanism of Action
Proteinase-activated receptor 4 (PAR-4) is a unique member of the G-protein-coupled receptor (GPCR) family. Unlike many receptors that require complex binding interactions, PAR4 is effectively "tethered" and activated through a proteolytic cleavage event. My A proteinase-activated receptor-4 (PAR-4) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist. review of recent literature suggests that PAR4 can be activated either by the native protease thrombin cleavage event or by a synthetic soluble agonist peptide mimicking the tethered ligand.
The PAR-4 agonist peptide serves as a vital proxy in these studies. Specifically, the PAR-4 agonist peptide sti Selective Inhibition of PAR4 (Protease-Activated Receptor 4) mulates thromboxane production by human platelets, providing researchers with a controlled method to observe signaling cascades without the need for high concentrations of native thrombin. It is important to note that PAR4 requires ≈10-fold more thrombin for proteolysis compared to othe PAR4 Antagonists (BMS-986120, BMS-986141) r receptors like PAR1, making the use of a synthetic PAR-4 Agonist Peptide, amide an essential requirement for precise, reproducible results.
Key Characteristics and Experimental Use
When conducting experiments, specificity PAR4 | Proteinase-activated receptors is paramount. The PAR-4-AP (TFA) is a selective agonist for Proteinase-Activated Receptor 4 (PAR-4), showing no cross-reactivity with PAR-1 or PAR-2. This selectivity allows for the isolation of PAR4-mediated responses.
* AY-NH2 is a selective PAR4 receptor agonist peptide that has been widely validated in laboratory settings.
* The PAR4 specific agonist peptide, AYPGKF is another iteration often utilized for probing signaling pathways in culture systems.
* Eviden Protease‐activated receptor 4: from structure to function and ce shows that the amino terminus of the fourth protease-activated receptor (PAR4) is effectively mimicked by these synthetic variants, which are readily activated both wild-type and mutant PAR4 receptors.
Physiological Context and Future Directions
The broader context of this research often touches on how PARs are activated by proteases generated during tissue damage. Because PAR4 plays a role in vari PARs are activated by proteases generated during tissue damage, contributing to tissue responses such as hemostasis, repair, cell survival, inflammation, ous cellular responses, it is highly relevant to studies involving inflammation and tissue repair.
Interestingly, PAR4 targeting is a safer strategy for preventing thrombosis, and many researchers are investigating how it provides robust antithrombotic activity with low bleeding profiles compared to traditional methods. Furthermore, there is emerging interest in the idea that PAR4 inhibition may mitigate thrombin-associated inflammation and neurovascular pathology.
As a Proteinase-activated receptor (PAR)-4 enthusiast, I by X Han · 2018 · Cited by 35 — PAR1 is an efficient substrate and responds to subnanomolar thrombin. In contrast, PAR4 requires ≈10-fold more thrombin for proteolysis. have observed that PAR4 is a recently characterized thrombin receptor that continues to provide surprises. For those working with PAR4 (protease-activated receptor 4), the ability to utilize a PAR4 signal peptide in experimental designs has opened new doors for understanding how PAR4 uses its anionic cluster to interact with α-thrombin.
Observations on Specificity
It is worth noting that not all factors interact with these receptors in the same way. For instance, data indicates that complement factor C4a does not activate PAR1 or PAR4 on human platelets, which helps researchers further refine their focus on the specific activation pathways of the PAR 4 system.
As PAR4 is an emerging target for anti-platelet drugs, the continued refinement of the par 4 peptide as a research tool remains a high priority. Whether you are using the PAR-4-AP in a standard assay or exploring the nuances of 4-related signaling, the precision provided by these synthetic peptides is indispensable for modern molecular biology.
***
*Disclaimer: This article is for informational purposes for research professionals and does not constitute medical advice or recommendations for human consumption. All materials discussed are intended strictly for laboratory and research use.*